Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. - Wikidata - awgldk - TriplyDB

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q33988695

about

Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]Targeting gastrointestinal stromal tumors: the role of regorafenib Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Pazopanib in sarcomas: expanding the PALETTE p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.Targeted therapy for cancer: the gastrointestinal stromal tumor model.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches.Recent advances in the management of gastrointestinal stromal tumors.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Updates on the management of gastrointestinal stromal tumors.New therapeutic targets in soft tissue sarcoma.Adjuvant treatment of GIST: patient selection and treatment strategies.Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.Succinate dehydrogenase-deficient gastrointestinal stromal tumors.Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.Advances in sarcoma genomics and new therapeutic targets.KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Pathology of gastrointestinal stromal tumors.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.

P2860

Q21133528-3B856014-D1F5-49E8-8CBD-2AC7E21E10B0 Q26747162-4E92E14B-67FF-4E12-B1E1-92CA6E9E47DF Q26799387-59FABE0D-63BD-40C2-8188-262167B611FF Q26825050-249171F4-6587-4BF1-9C9A-572E353091F2 Q28483922-2588AE8B-A4D0-48C0-A5EE-733A57D10386 Q28543370-F2219FD5-FB2A-4456-9D65-AA3CAC548CB8 Q30245586-D7ABE350-6C24-4DC7-A507-E440215053CA Q33274455-EDBF6B39-C04F-4E15-ADB0-2B439068B716 Q33633409-B360F360-F257-4298-A3C8-4FACD499D709 Q33644791-62FCFD1B-568C-49A2-B773-67EF1FE647E5 Q33688428-ADF0704D-602A-4B1A-AED6-9EEB1BB85F83 Q33695315-5938D48A-DFA6-4561-8228-7BC668B06614 Q33802730-2B417ED9-518D-40BF-9BC7-828938B9625F Q33807742-8B801921-BCB1-4F6C-A71F-CCDBEE40F8BD Q33921067-83AB9F64-2549-44D8-87C6-66157C8C1038 Q34171517-FED1C278-C2CE-4EE9-8F3F-B5674EE88E21 Q34175620-C41DB134-2BA7-4201-A196-25CBBF96C8D2 Q34202396-C11C8D9F-09C4-4B62-9FE1-9550563E6A8C Q34256921-33CF6AB0-7236-48FE-8B8A-6DF2FD0280AA Q34267924-315A4CD9-3AB9-45A4-BF38-92A584BAA5AF Q34270274-881BD627-D8D4-4643-A589-701A34CDF87D Q34274467-19FF5728-3B25-4882-9726-DA9E78615086 Q34300784-E4350774-689D-488B-AE41-A92DEE23C5D3 Q34668378-CE56A191-09CE-4A52-8D0E-8F77CFF05E23 Q35041245-02386899-3057-45E3-829E-65FFF787D5EA Q35273302-9694B486-BF29-4038-9B58-5FD5647C201D Q35350491-BB1B761B-0FA3-493C-9E6B-9955507C4C68 Q35837219-874B45C4-73DA-45C3-A51D-1D673BE63F3B Q35993346-AD847081-F5D7-41CD-B7D5-580524EB719C Q36025994-C2149C17-8CB5-4083-A9A3-18233DCBB9AF Q36125976-8F64EBD9-2469-47DC-AE25-EFF8660007B0 Q36129663-2FB73E81-89CB-4D3B-A9B0-97B8D25C04DA Q36140332-8BDAA1D2-1A69-4675-852F-735677E0A32E Q36180074-20A326A7-F955-4971-A7CE-07BD7D5B4A18 Q36383438-34E633EA-AF15-4D1B-AA62-2E2DC84E2CA3 Q36447011-AD9D3865-F07E-455F-A2BC-42A490428ABD Q36509363-6178E128-E602-4616-A847-093E34097DB1 Q36561734-42485C2D-77FE-46F3-9A67-A1A17C83128C Q36577759-A84B1810-3743-46C0-B02C-563C1806141D Q36587153-8367C028-1423-461D-9F6A-6F3D95E4A92B

P2860

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q33988695

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@ast

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@en

type

label

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@ast

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@en

prefLabel

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@ast

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@en

P1433

Q33988695-17E71BF7-BA53-4ACA-B367-E77D7501C1BA

P1476

Q33988695-063DA536-51E2-43E0-B279-D025FA04060E

P2093

Q33988695-483BB08E-D194-4BAD-BA65-BD23961E506D

Q33988695-4A56010F-C69A-4DAB-8765-6FD7485217A5

Q33988695-734CE6BC-B4B2-4808-9E28-024EE5C230AA

Q33988695-794C0076-CF7B-49C9-861D-2F4064F1324B

Q33988695-798E1D57-67FB-41E2-887A-BCADDB1FCBD4

Q33988695-C48CC002-29AC-4293-94F2-915BA9E2535E

Q33988695-D6C855D4-D863-49D6-B67E-111D4A8F9009

Q33988695-FF644510-0828-4E82-A9FF-BABF348CBE37

P2860

Q33988695-08ADF8E2-B16D-47E7-A59C-DC4B4DFB77C0

Q33988695-0B46AFB9-EC64-4D2C-8B98-CFFC2A72F814

Q33988695-0C69D4D4-7142-4F45-BFC4-9ACE77C534F6

Q33988695-2005259D-E31D-4875-85BF-B30DB8507A23

Q33988695-28996F47-8DED-448F-A898-7BCA1E6FDEC8

Q33988695-4E149D4F-6A89-4E76-8699-B81AEF1E2F93

Q33988695-503776D5-2B2A-45F3-B035-FB6A99A0DAD1

Q33988695-51A238F7-7B66-4F29-9ECD-5F541F19FD4D

Q33988695-52568FF3-DA3D-4DEA-A5E5-7AA33B6448C9

Q33988695-6A38F597-DB6E-47CD-AB2C-D32190FC40BB

P304

Q33988695-7B7F4AA6-CABB-42C7-80DF-CC6056C5F7D0

P31

Q33988695-500F8456-62B5-414F-B147-06691DFA07E1

P356

Q33988695-37EBC48F-400F-4CC1-82CE-6E56F32B95A9

P433

Q33988695-E0C791CB-F44B-4E51-9F94-82104F6AAC00

P478

Q33988695-E944D80D-3018-4D95-98AC-7A4FEA611B28

P577

Q33988695-6A0AC4B5-4A84-4D52-BC5B-9E44AC369065

P5875

Q33988695-481336C6-0F3C-47F1-ADD8-08C80D69573C

P698

Q33988695-28F5B136-C772-4EDA-850E-3192199F71E4

P932

Q33988695-9564A783-BE9F-4D42-BEDA-FDD6067A9BC6

P356

P1433

Genes, Chromosomes and Cancer

P1476

Novel V600E BRAF mutations in ...... strointestinal stromal tumors.

@en

P2093

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Grace C Wong

http://www.w3.org/2001/XMLSchema#string

Narasimhan P Agaram

http://www.w3.org/2001/XMLSchema#string

Peter Besmer

http://www.w3.org/2001/XMLSchema#string

Robert G Maki

http://www.w3.org/2001/XMLSchema#string

Ronald P Dematteo

http://www.w3.org/2001/XMLSchema#string

Samuel Singer

http://www.w3.org/2001/XMLSchema#string

Tianhua Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

Mutations of the BRAF gene in human cancer

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

BRAF mutation predicts sensitivity to MEK inhibition

Distinct sets of genetic alterations in melanoma

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Mutations of the human PTEN gene.

PDGFRA activating mutations in gastrointestinal stromal tumors.

P304

853-859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GCC.20589

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5236374

http://www.w3.org/2001/XMLSchema#string

P698

18615679

http://www.w3.org/2001/XMLSchema#string

P932

2902874

http://www.w3.org/2001/XMLSchema#string